GlassScriptPhysician profile
Kevin G Cleary
NPI 1831156447
$3,265.44
in general payments reported to CMS, 2019-2025
30 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $381 · 2021: $658 · 2022: $739 · 2023: $394 · 2024: $284 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $985.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $847.75 | 2019-2025 | Qulipta, Vraylar |
| Novo Nordisk INC | $388.40 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $217.15 | 2019-2023 | Spravato |
| Amgen INC. | $211.77 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $181.81 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $175.71 | 2019-2025 | Freestyle Libre 3 |
| Pfizer INC. | $156.91 | 2019-2025 | |
| Ethicon US, LLC | $122.69 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $101.74 | 2019-2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $86.30 | 2020-2022 | |
| Astellas Pharma US INC | $85.58 | 2019-2021 | |
| Nevro Corp. | $75.37 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $68.96 | 2019-2024 | Breztri |
| Ibsa Pharma INC. | $68.34 | 2024-2025 | Tirosint, Licart, Flector |
| Daiichi Sankyo INC. | $64.67 | 2019-2024 | Injectafer |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $55.57 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $52.37 | 2021-2022 | |
| Lilly USA, LLC | $47.63 | 2020-2021 | |
| Dexcom, INC. | $44.36 | 2023-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $31.17 | 2020-2022 | |
| Edwards Lifesciences Corporation | $26.00 | 2020 | |
| Mannkind Corporation | $24.95 | 2020 | |
| Gilead Sciences, INC. | $18.27 | 2021 | |
| Grifols USA, LLC | $17.67 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.66 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.36 | 2019 | |
| Valeritas, INC. | $15.96 | 2019 | |
| Dermira, INC. | $15.41 | 2020 | |
| Scilex Pharmaceuticals INC. | $14.52 | 2020 | |
| Endo Pharmaceuticals INC. | $14.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Cleary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.